|
1
|
Ritz E and Orth SR: Nephropathy in
patients with type 2 diabetes mellitus. N Engl J Med.
341:1127–1133. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Remuzzi G, Schieppati A and Ruggenenti P:
Clinical practice: Nephropathy in patients with type 2 diabetes. N
Engl J Med. 346:1145–1151. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Kolset SO, Reinholt FP and Jenssen T:
Diabetic nephropathy and extracellular matrix. J Histochem
Cytochem. 60:976–986. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tervaert TW, Mooyaart AL, Amann K, Cohen
AH, Cook HT, Tervaert TW, Mooyaart AL, Amann K, Cohen AH, Cook HT,
Drachenberg CB, Ferrario F, Fogo AB, Haas M, de Heer E, et al:
Pathologic classification of diabetic nephropathy. J Am Soc
Nephrol. 21:556–563. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Phillips CA and Molitch ME: The
relationship between glucose control and the development and
progression of diabetic nephropathy. Curr Diab Rep. 2:523–529.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Mishra R, Emancipator SN, Kern T and
Simonson MS: High glucose evokes an intrinsic proapoptotic
signaling pathway in mesangial cells. Kidney Int. 67:82–93. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Cooper ME: Interaction of metabolic and
haemodynamic factors in mediating experimental diabetic
nephropathy. Diabetologia. 44:1957–1972. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Ha H and Lee HB: Reactive oxygen species
as glucose signaling molecules in mesangial cells cultured under
high glucose. Kidney Int Suppl. 77:S19–S25. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gao Q, Qin WS, Jia ZH, Zheng JM, Zeng CH,
Li LS and Liu ZH: Rhein improves renal lesion and ameliorates
dyslipidemia in db/db mice with diabetic nephropathy. Planta Med.
76:27–33. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brosius FC III: New insights into the
mechanisms of fibrosis and sclerosis in diabetic nephropathy. Rev
Endocr Metab Disord. 9:245–254. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wang JY, Yin XX, Wu YM, Tang DQ, Gao YY,
Wan MR, Hou XY and Zhang B: Ginkgo biloba extract suppresses
hypertrophy and extracellular matrix accumulation in rat mesangial
cells. Acta Pharmcol Sin. 27:1222–1230. 2006. View Article : Google Scholar
|
|
12
|
Lal MA, Brismar H, Eklöf AC and Aperia A:
Role of oxidative stress in advanced glycation end product-induced
mesangial cells activation. Kidney Int. 61:2006–2014. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Dronavalli S, Duka I and Bakris GL: The
pathogenesis of diabetic nephropathy. Nat Clin Pract Endocrinol
Metab. 4:444–452. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang JY, Yin XX, Wu YM, Tang DQ, Gao YY,
Wan MR, Hou XY and Zhang B: Ginkgo biloba extract suppresses
hypertrophy and extracellular matrix accumulation in rat mesangial
cells. Acta Pharmacol Sin. 27:1222–1230. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Xu W, Shao X, Tian L, Gu L, Zhang M, Wang
Q, Wu B, Wang L, Yao J, Xu X, et al: Astragaloside IV ameliorates
renal fibrosis via the inhibition of mitogen-activated protein
kinases and antiapoptosis in vivo and in vitro. J Pharmacol Exp
Ther. 350:552–562. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sato S, Kawamura H, Takemoto M, Maezawa Y,
Fujimoto M, Shimoyama T, Koshizaka M, Tsurutani Y, Watanabe A, Ueda
S, et al: Halofuginone prevents extracellular matrix deposition in
diabetic nephropathy. Biochem Biophys Res Commun. 379:411–416.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rios JL and Waterman PG: A review of the
pharmacology and toxicology of Astragalus. Phytother Res.
11:411–418. 1997. View Article : Google Scholar
|
|
18
|
Liu G, Song J, Guo Y, Wang T and Zhou Z:
Astragalus injection protects cerebral ischemic injury by
inhibiting neuronal apoptosis and the expression of JNK3 after
cerebral ischemic reperfusion in rats. Behav Brain Funct. 9:362013.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wei XP, Wu ZL and Wang JT: Clinical
research on treating diabetes with Astragalus injection and
TMP injection. Zhongguo Lin Chuang Yan Jiu. 6:142014.(In
Chinese).
|
|
20
|
Xu M, Yin J, Xie L, Zhang J, Zou C, Zou J,
Liu F, Ju W and Li P: Pharmacokinetics and tolerance of total
astragalosides after intravenous infusion of astragalosides
injection in healthy Chinese volunteers. Phytomedicine.
20:1105–1111. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Mason RM and Wahab NA: Extracellular
matrix metabolism in diabetic nephropathy. J Am Soc Nephrol.
14:1358–1373. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nakajima T, Haseqawa G, Kamiuchi K, Fukui
M, Yamasaki M, Tominaga M, Asano M, Hosoda H, Yoshikawa T and
Nakamura N: Differential regulation of intracellular redox state by
extracellular matrix proteins in glomerular mesangial cells:
Potential role in diabetic nephropathy. Redox Rep. 11:223–230.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Sakharova OV, Taal MW and Brenner BM:
Pathogenesis of diabetic nephropathy: Focus on transforming growth
factor-beta and connective tissue growth factor. Curr Opin Nephrol
Hypertens. 10:727–738. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Zhao TT, Zhang HJ, Lu XG, Huang XR, Zhang
WK, Wang H, Lan HY and Li P: Chaihuang-Yishen granule inhibits
diabetic kidney disease in rats through blocking TGF-β/Smad3
signaling. PLoS One. 9:e908072014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sharma K and Ziyadeh FN: Renal hypertrophy
is associated with upregulation of TGF-beta 1 gene expression in
diabetic BB rat and NOD mouse. Am J Physiol. 267:F1094–F1101.
1994.PubMed/NCBI
|
|
26
|
Border WA and Noble NA: Evidence that
TGF-beta should be a therapeutic target in diabetic nephropathy.
Kidney Int. 54:1390–1391. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Liu X, Luo F, Pan K, Wu W and Chen H: High
glucose upregulates connective tissue growth factor expression in
human vascular smooth muscle cells. BMC Cell Biol. 8:12007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Guha M, Xu ZG, Tung D, Lanting L and
Natarajan R: Specific down-regulation of connective tissue growth
factor attenuates progression of nephropathy in mouse models of
type 1 and type 2 diabetes. FASEB J. 21:3355–3368. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Qi W, Chen X, Poronnik P and Pollock CA:
Transforming growth factor-beta/connective tissue growth factor
axis in the kidney. Int J Biochem Cell Biol. 40:9–13. 2008.
View Article : Google Scholar : PubMed/NCBI
|
